ICAM1 and autoimmune disease: Targeting the interaction between ICAM-1 and LFA-1 as a treatment for (auto)immunity has been the subject in a number of studies (reviewed in [17]), and was shown to have beneficial effects in animal models for autoimmune diseases [9], [10].